| Literature DB >> 28623027 |
Ruth Aralí Martínez-Vega1, Gabriel Carrasquila2, Expedito Luna3, José Ramos-Castañeda4.
Abstract
The vaccine against Dengue virus (DENV), Dengvaxia® (CYD), produced by Sanofi-Pasteur, has been registered by several national regulatory agencies; nevertheless, the performance and security of this vaccine have been challenged in a series of recent papers. In this work, we intend to contribute to the debate by analyzing the concept of an enhancing vaccine, presenting objections to the epidemiological model base of the concept and, likewise, presenting data that contradict that concept.Entities:
Keywords: Dengue; Immunity; Pathogenesis; Vaccine
Mesh：
Substances：
Year: 2017 PMID： 28623027 DOI： 10.1016/j.vaccine.2017.06.004
Source DB: PubMed Journal: Vaccine ISSN： 0264-410X Impact factor: 3.641